Author(s): Goutham Yerrakula, Samuel Gideon George, PR Anand Vijaya Kumar, Krishna Kumar D, Senthil Venkatachalam

Email(s): senthiljssooty@gmail.com

DOI: 10.52711/0974-360X.2022.00808   

Address: Goutham Yerrakula1, Samuel Gideon George2, PR Anand Vijaya Kumar3, Krishna Kumar D4, Senthil Venkatachalam1*
1Department of Pharmaceutics, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu.
2Department of Pharmacy Practice, Krupanidhi College of Pharmacy, Banglore.
3Department of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education and Research, Ooty, The Nilgiris, Tamil Nadu.
4Department of Pharmacy Practice, Karpagam College of Pharmacy, Coimbatore.
*Corresponding Author

Published In:   Volume - 15,      Issue - 10,     Year - 2022


ABSTRACT:
Atrial fibrillation (AF) is also the most common cause of cerebrovascular morbidity and mortality in cardioembolic stroke patients. In patients with AF, oral anticoagulation treatment has shown to minimise the risk of cardioembolic stroke by more than half. Anticoagulation with vitamin K antagonists is best used with strict adherence and monitoring. Patient dissatisfaction can be caused by a number of causes, all of which lower the patient's excellence of life. New immediate oral anticoagulants, for example, the immediate factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, and the dabigatran thrombin inhibitor, were intended to defeat the shortcomings of conventional anticoagulant drugs. However, models to boost the estimation of treatment and guarantee that treatment can be securely proceeded are missing for existing oral anticoagulants. This survey will briefly examine the new oral anticoagulants dabigatran, apixaban, edoxaban, and rivaroxaban, with an attention on their utilization in the anticipation of embolic events in AF. It will look at the benefits for patients of life, just as the protection and adequacy of the treatment.


Cite this article:
Goutham Yerrakula, Samuel Gideon George, PR Anand Vijaya Kumar, Krishna Kumar D, Senthil Venkatachalam. Ensuring safety of Novel Oral Anticoagulants Predictable Dose Response Relationship. Research Journal of Pharmacy and Technology 2022; 15(10):4812-8. doi: 10.52711/0974-360X.2022.00808

Cite(Electronic):
Goutham Yerrakula, Samuel Gideon George, PR Anand Vijaya Kumar, Krishna Kumar D, Senthil Venkatachalam. Ensuring safety of Novel Oral Anticoagulants Predictable Dose Response Relationship. Research Journal of Pharmacy and Technology 2022; 15(10):4812-8. doi: 10.52711/0974-360X.2022.00808   Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-10-81


REFERENCES:
1.    Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep. 2013;1(2):83-97. doi:10.1007/s40138-013-0014-6
2.    Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):e44S-e88S. doi:10.1378/chest.11-2292
3.    Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 SUPPL.):e24S-e43S. doi:10.1378/chest.11-2291
4.    Mustonen P, Puurunen M. [New antithrombotic drugs]. Duodecim. 2012;128(7):707-718. doi:10.1378/chest.11-2294
5.    Becattini C, Vedovati MC, Agnelli G. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: A review of the literature. Thromb Res. 2012;129(3):392-400. doi:10.1016/j.thromres.2011.12.014
6.    Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 SUPPL. 6):160S-198S. doi:10.1378/chest.08-0670
7.    Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: Pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):1. doi:10.1186/1477-9560-11-10
8.    Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743-753. doi:10.1177/0091270009351883
9.    Stangier J, Clemens A. Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor. Clin Appl Thromb. 2009;15(1_suppl):09S-16S. doi:10.1177/1076029609343004
10.    Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: Implications for treatment. Drug Des Devel Ther. 2013; 8:49-65. doi:10.2147/DDDT.S6762
11.    Borawski J, Dubowski M, Rydzewska-Rosolowska A, Mysliwiec M. Intravenous and oral sulodexide versus coagulation activation markers in humans. Clin Appl Thromb. 2009;15(5):596-598. doi:10.1177/1076029609333674
12.    Piccini JP, Hellkamp AS, Washam JB, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133(4):352-360. doi:10.1161/CIRCULA TIONAHA .115.018544
13.    Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: An analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288-2295. doi:10.1016/S0140-6736(14)61943-7
14.    Article R. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. Published online 2013:245-252. doi:10.1111/jth.12096
15.    Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban : Guidance from the British Committee for Standards in Haematology. Published online 2012. doi:10.1111/bjh.12052
16.    Healey JS, Eikelboom J, Douketis J, et al. Peri-Procedural Bleeding and Thromboembolic Events with Dabigatran Compared to Warfarin : Results from the RE-LY Randomized Trial. Published online 2012. doi:10.1161/CIRCULATIONAHA .111.090464
17.    Hacke W, Ph D, Breithardt G, et al. new england journal. Published online 2011:883-891.
18.    Flaker GC, Eikelboom JW, Shestakovska O, et al. Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial. Published online 2012. doi:10.1161/STROKEAHA.112.664144
19.    Wallentin L, Lopes RD, Hanna M, et al. Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of Predicted INR Control for Stroke Prevention in Atrial Fibrillation Address for Correspondence : Lars Wallentin MD , PhD doi:10.1161/CIRCULATIONAHA.112.142158
20.    Mani H, Kasper A, Lindhoff-last E. Measuring the anticoagulant effects of target specific oral anticoagulants — reasons, methods and current limitations. Published online 2013:187-194. doi:10.1007/s11239-013-0907-y
21.    New oral antithrombotics : a need for laboratory monitoring . For. Published online 2010:621-626. doi:10.1111/j.1538-7836.2010.03764.x
22.    Upreti V V, Wang J, Barrett YC, et al. Effect of extremes of body weight on the and tolerability of apixaban in healthy subjects WHAT IS ALREADY KNOWN ABOUT. Published online 2013. doi:10.1111/bcp.12114
23.    Commentary SI. The Use of Dabigatran in Elderly Patients. 2015;171(14):1285-1286.
24.    Goethe-university JW, Goethe-university JW. New oral anticoagulants in patients with nonvalvular atrial fibrillation : a review of pharmacokinetics , safety , efficacy , quality of life , and cost effectiveness. Published online 2014:789-798.
25.    Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of Oral Anticoagulants in Atrial Fibrillation : A Systematic Review. AJM. 2010;123(7):638-645.e4. doi:10.1016/j.amjmed.2009.11.025
26.    Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range. Published online 2015. doi:10.1161/ Circulationaha.107.750000
27.    Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of Adherence, Knowledge, and Quality of Life on Anticoagulation Control. 2005; 39:632-636. doi:10.1345/aph.1E464
28.    Samama MM, Contant G, Spiro TE, et al. Clinical and Applied Thrombosis / Hemostasis Evaluation of the Prothrombin Time for Controls : Results of a Multicenter Field Trial. Published online 2012. doi:10.1177/1076029611426282
29.    Mani H, Rohde G, Stratmann G, et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Published online 2012:191-198. doi:10.1160/TH11-12-0832
30.    Curvers J, Kerkhof D Van De, Stroobants AK, Sam CME. Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays Which Assay Is Helpful ? Published online 2012:551-558. doi:10.1309/AJCPQOD9WFPEYY0H
31.    Adamu Yau, Nordin Bin Simbak, Mainul Haque. Pharmacogenovigilance: A Potential Tool in Pharmacovigilance. Research J. Pharm. and Tech. 7(12): Dec. 2014; Page 1476-1482
32.    Suraj S. Gaba III BDS Student, Saveetha Dental College, Chennai, India, Research J. Pharm. and Tech. 7(10): October 2014; Page 1187-1189
33.    Ruheena Yasmeen, N. Krishna Reddy, Marina. G. D’ Souza, B. Swathi, Anas Abdul Waheed, Katakam Chinmayee, J. Vineeth Reddy. Study of Anticoagulants low molecular weight heparin and Unfractionated heparin in the management of Non-St elevation Myocardial Infarction. Research J. Pharm. and Tech. 2020; 13(7): 3151-3155. https://doi.org/10.5958/0974-360X.2020.00557.0

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available